Medicamen Biotech Limited (MEDICAMEQ) Stock Price & Analysis

MEDICAMEQ Stock Chart & Stats

₹255.50-₹11.90(-4.45%)

At close: Oct 30 3:30 PM GMT+5:30

Day’s Range: INR 254.05 - INR 270.10
52-Week Range: INR 210.10 - INR 454.00
Previous Close: INR 267.40
Volume: 10.37K
Average Volume (3M): 2,079
Market Cap: INR 3.47B
Enterprise Value: INR 3.02B
Total Cash (Recent Filing): INR 312.64M
Total Debt (Recent Filing): INR 0
Price to Earnings (P/E): 32.0
Beta: 1.07
Next Earnings: Nov 06, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Sep 18, 2026
Dividend Yield: 0.39%

Bulls Say, Bears Say

Bulls Say

Recent Revenue Growth

The return to strong revenue growth shows renewed demand or execution across the company’s formulation business. If sustained, higher sales can improve operating scale, support reinvestment, and strengthen the company’s ability to build earnings over the next several quarters.

Conservative Balance Sheet

Moderate leverage and substantial equity expansion provide financial resilience and reduce dependence on borrowing to support operations. This balance-sheet position gives Medicamen greater flexibility to fund growth and withstand periods of weaker profitability than a highly levered peer.

Formulation Business Scope

A focus on multiple finished-dosage formats and both domestic and export markets gives the business a broad operating base. This product and geographic scope can support recurring formulation demand and reduce reliance on a single dosage category or market.

Bears Say

Persistent Negative Cash Flow

Sustained negative operating and free cash flow indicates that reported profits are not converting into liquidity. The resulting funding needs can constrain investment, increase reliance on financing or working-capital management, and weaken financial flexibility if the pattern persists.

Weaker Profitability

The decline in net income and thin recent margin show that revenue growth has not translated consistently into stronger earnings. Lower profitability reduces internal funding capacity and leaves the business more exposed to operating pressure over the next several quarters.

Lower Capital Returns

Falling return on equity suggests the expanding capital base is producing less profit per unit of shareholder funding. Unless profitability improves, this weaker capital efficiency could limit the long-term value created from retained earnings and balance-sheet growth.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that it received a cautionary letter from the National Stock Exchange of India

8M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹210.10 and its highest was ₹454.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.47B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Aug 14, 2026. The company reported ₹1.562 earnings per share for the quarter.

Is Medicamen Biotech Limited overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.39%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.562 in its last earnings report. Following the earnings report the stock price went down -0.824%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description